Allergan (NYSE:AGN) said today that it won FDA approval for its Xen gel stent and injector for glaucoma. The federal watchdog indicated the drug device for the management of refractory glaucoma, in cases where surgical treatment has failed or in patients with open angle glaucoma that is unresponsive to maximum tolerated medical therapy. The Dublin-based […]
Allergan
Sofregen buys Allergan’s Seri surgical scaffold
Sofregen Medical said today that it bought the Seri surgical scaffold from Allergan (NYSE:AGN) for an undisclosed amount. Polaris Partners and other investors provided financing for the acquisition, according to the Medford, Mass.-based company. Seri, which is approved by the FDA for use as soft tissue support in plastic and reconstructive surgical procedures, is the only approved […]
Allergan wins FDA nod for Natrelle Inspira breast implants
Allergan (NYSE: AGN) said last week that it won FDA pre-market approval for its Natrelle Inspira cohesive breast implants for women undergoing breast reconstruction, augmentation or revision surgery. The newly cleared Natrelle Inspira implants combine both a high gel fill ratio and the company’s cohesive gel to create a customized shape, the company said. “Natrelle […]
Seno Medical grabs ex-CeloNova CFO Davis | Personnel Moves August 12, 2016
Seno Medical grabs ex-CeloNova CFO Davis Seno Medical Instuments said this week it tapped former CeloNova BioSciences chief financial officer Eric Davis to take over the CFO role at Seno Medical. Prior to his years at CeloNova, Davis operated as CFO and operating officer at Genesis Networks Enterprises. Seno Medical said that Davis has more than […]
Allergan picks up ForSight Vision for $95m
Allergan (NYSE: AGN) said today it inked a deal to buy drug-eluting ophthalmological implant maker ForSight Vision5 for $95 million up front, with a possible milestone payment for launching its drug-eluting device. Pharmaceutical giant Allergan said the device, known as the Helios ring, is designed for extended drug delivery and for reducing intraocular pressure in […]
Allergan asks FDA to approve Oculeve neurostim device
Allergan (NYSE:AGN) said today that it filed a de novo approval application with the FDA for its Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last […]
Could pharma exec’s acquittal help accused ex-Acclarent officials?
The acquittal last week of a former pharmaceutical executive, charged in a kickbacks scheme to win business from doctors, could prove a boon for a pair of medical device executives facing similar charges. A jury in Massachusetts federal court cleared former Warner Chilcott pharmaceutical president Carl Reichel of charges that he coach sales reps to woo doctors by taking them to expensive […]
Allergan touts FDA acceptance of 510(k) application for Xen IOP reducing gel shunt
Allergan (NYSE: AGN) said today the FDA accepted the 510(k) premarket notification application for its Xen glaucoma treatment gel stent system, which consists of the Xen45 gel stent and Xen injector. The system is a minimally invasive implantable, crosslinked gelatin shunt designed to reduce intraocular pressure associated with refractory glaucoma, according to the company. The […]
Allergan’s Oculeve on track for FDA submission this year
Allergan (NYSE:AGN) said today that it’s on track for an FDA submission this year for the Oculeve nasal neurostimulation device for dry eye it bought last year. Oculeve is a hand-held device designed to be inserted into the nostril to stimulate the nerves serving the lacrimal gland. Allergan paid $125 million plus unspecified milestones for Oculeve last year. Today the […]
Medtronic still unfazed by new inversion rules
Medtronic (NYSE:MDT) remains unfazed by the U.S. Treasury Dept.’s push to rein in so-called “inversion” mergers, which allow American companies to re-organized under foreign jurisdictions, after the agency issued new rules on the deals this week. The U.S. government has grappled with a wave of inversions in recent years, including last year’s $50 billion union of Medtronic and Covidien, […]
UPDATE: Pfizer’s $160B Allergan buy sparks cry for tax-inversion crack down
Updated with extra politician comments and tax-inversion data. Pfizer (NYSE:PFE) said today it will buy Botox maker Allergan (NYSE: AGN) for approximately $160 billion and slash its tax bill in the largest-ever tax inversion to date. To avoid restrictions, smaller, Dublin-based Allergan is buying Pfizer, though the combined company will still be known as Pfizer and will still be […]